Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (NYSE: DGX) is a medical laboratories company focused on diagnostic testing and diagnostic information services, and its news flow reflects its role across the healthcare ecosystem. The company regularly issues updates on its financial reporting schedule, including announcements about quarterly and full-year results and related conference calls, which are of interest to investors tracking DGX stock and performance trends.
News about Quest Diagnostics also covers participation in major healthcare and investor conferences. For example, the company has announced presentations at events such as the J.P. Morgan Healthcare Conference and Citi’s Global Healthcare Conference, where its leadership discusses strategy, performance and market developments. These appearances provide insight into how the company views its position in the diagnostic testing and information services market.
Quest Diagnostics’ news includes information on collaborations and joint ventures that expand access to laboratory services. Announcements have highlighted a laboratory services joint venture with Corewell Health in Michigan, as well as the ongoing role of Sonora Quest Laboratories, an Arizona-based joint venture between Banner Health and Quest Diagnostics. Such items help readers understand how Quest Diagnostics partners with health systems to deliver regional laboratory services and hospital lab management solutions.
In addition, Quest Diagnostics reports on developments in specialized diagnostics through subsidiaries and collaborations. News has featured Haystack MRD, a minimal residual disease test developed by Haystack Oncology, a wholly owned subsidiary of Quest Diagnostics, including data presentations at scientific meetings and clinical research collaborations. Other coverage has described a strategic collaboration with Octave Bioscience to expand access to the Octave Multiple Sclerosis Disease Activity Test through Quest’s specimen-collection network.
Visitors to the DGX news page can review these types of updates to follow financial communications, strategic partnerships, scientific data presentations and corporate announcements that shape Quest Diagnostics’ activities in the medical laboratories sector.
Quest Diagnostics (NYSE: DGX) released its 2023 Corporate Responsibility Report, emphasizing its ESG initiatives under the theme 'Care at Our Core'. The report highlights the company's four strategic pillars: Employee and Community Engagement, Equity and Health Access, Governance and Ethics, and Environmental Sustainability.
Key achievements in 2023 include over $16 million in corporate giving, approximately 950,000 donated or discounted test requisitions, and more than 30,000 employee volunteer hours. The company also launched the HealthyQuest Employee Business Network and received ISO 14001 certification for its laboratories in Cleveland, OH, and Chantilly, VA.
Quest Diagnostics continues to enhance its processes and capabilities to support its ESG goals, aiming to create a healthier world through collaboration with various stakeholders.
Quest Diagnostics (NYSE: DGX) announced a definitive agreement to acquire select laboratory assets from Allina Health. This acquisition aims to enhance access to Quest's cost-effective and innovative laboratory services throughout Minnesota and western Wisconsin.
According to Quest's Chairman, CEO, and President Jim Davis, the transaction aligns with Quest's strategy to expand its service offerings and generate growth through accretive acquisitions.
The deal, expected to close in Q3 2024 pending regulatory approval, will allow Quest to serve Allina Health clinic physicians and outreach provider clients across the region. Financial details of the transaction were not disclosed.
Quest Diagnostics (NYSE: DGX), a prominent player in diagnostic information services, announced it will release its Q2 2024 financial results on July 23, 2024, before the market opens.
The company will also hold a conference call at 8:30 a.m. ET to discuss the results. Interested parties in the U.S. and Canada can dial 888-455-0391, while international participants can use 773-756-0467, with the passcode '7895081'.
The earnings release and live webcast will be available on www.QuestDiagnostics.com/investor. A replay of the call will be accessible online and by phone until midnight ET on August 6, 2024.
Listeners are encouraged to review periodic reports filed with the SEC for additional discussions on risk factors and financial conditions.
Mark Hamilton, a STAT driver for Quest Diagnostics, shares his career journey and experiences in a recent press release. Mark highlights his transition from the airline industry to healthcare, emphasizing the importance of handling specimens with care and precision. He describes his commitment to ensuring that samples such as blood, urine, tissue, and skin grafts are transported under optimal conditions and correctly labeled. Mark also stresses the significance of communication and collaboration with clients to improve services and ensure long-term satisfaction. Through his work at Quest, he finds personal fulfillment and values the role he plays in patient care.
Quest Diagnostics (NYSE: DGX) has completed the acquisition of PathAI Diagnostics from PathAI to accelerate AI and digital pathology adoption for cancer diagnosis. PathAI will remain independent, advancing AI solutions for biopharmaceutical companies and pathology labs. The Memphis lab is rebranded as AmeriPath, serving as Quest’s national AI and digital R&D center. Quest will license PathAI's AISight™ system and collaborate on AI development for research and clinical applications. Quest aims to enhance quality and efficiency through AI integration in its services.
Quest Diagnostics announced the election of Robert B. Carter, CIO of FedEx, to its Board of Directors. Carter, 64, has spent over three decades at FedEx, where he will soon step down from his executive roles but remain as an advisor until December. His expertise in technology, particularly in cloud technologies and cybersecurity, is expected to benefit Quest Diagnostics as it aims to leverage IT and generative AI to enhance its business. Quest's Board now includes 10 members. Carter also holds board positions at New York Life and previously at First Horizon and Saks.
Quest Diagnostics celebrated Lab Week 2024, honoring medical laboratory professionals and pathologists across the U.S. The event highlighted the career journey of Lisa Szeto-Tay, from a phlebotomist to a Group Lead, Medical Laboratory Scientist, at Quest's Rapid Response Laboratory in Cambridge, MA. Lisa emphasized her career evolution, beginning with phlebotomy and advancing through various technical roles due to continuous education and company support, including tuition reimbursement and training programs like EMPower and Smartsolve. She advised dependability and continuous improvement as keys to career progression.
On June 5, 2024, Quest Diagnostics' Director of Sustainability, Karen Braun, visited East Norriton Middle School to engage with Healthy NewsWorks student reporters. Healthy NewsWorks, a grantee of Quest for Health Equity, empowers students to become skilled health journalists.
During the visit, Karen discussed Quest Diagnostics' commitment to sustainability, including reducing single-use plastic waste by 105 standard tons in 2022 through modified specimen cups and stool containers. She highlighted the importance of continuous improvement and employee engagement in sustainability initiatives.
The students were inspired to launch a 'Look in Your Lunchbox' project to minimize cafeteria waste and explore composting opportunities. Karen's interview will be featured in the fall edition of For Kids, By Kids magazine.
The spring edition of the magazine includes a foreword by Quest for Health Equity Executive Director Michael Floyd. Further details on Quest's sustainability efforts can be found in their 2022 Corporate Responsibility Report.
A study published in JAMA Health Forum suggests that blood-based minimal residual disease (MRD) testing, specifically the Haystack MRD™ ctDNA test, can reduce healthcare costs in colorectal cancer treatment. Conducted by Quest Diagnostics and its subsidiary Haystack Oncology, the study found that testing half of eligible stage II colorectal cancer patients could cut costs by up to 21%. The study showed that ctDNA MRD tests could help identify patients who may safely skip chemotherapy, reducing both costs and adverse events. Results showed cost savings of $221,684 for commercial plans and $116,720 for Medicare Advantage plans, assuming 50% of eligible patients are tested. The findings are significant, considering that colorectal cancer is among the most diagnosed cancers in the U.S., with over 106,970 new cases projected in 2023.
Quest Diagnostics celebrated Lab Week 2024, acknowledging the contributions of medical laboratory professionals and pathologists nationwide.
A highlight of the event was the career journey of Mimi Perdue-Loan, a Change Management Director in the Great Midwest Region, who has been with Quest for 44 years. Mimi shared insights on career progression, the importance of continuous improvement, and the impact of new technologies in healthcare. She emphasized the value of cross-functional team participation and networking within the organization to discover one’s true passion in the field.
Mimi also highlighted the significance of Quest's tools such as Six Sigma, Kaizen, and Total Quality Management in enhancing leadership skills and process excellence. Her advice to others includes volunteering for diverse roles and maintaining a customer-first approach. She remains committed to educating young students about careers in clinical lab science.